Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1359 - Autofluorescence: a new marker for identifying cancer stem cells (CSCs) in primary tumors

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Miriam López Gómez

Citation

Annals of Oncology (2018) 29 (suppl_8): viii670-viii682. 10.1093/annonc/mdy304

Authors

M. López Gómez1, E. Casado1, M. Muñoz2, S. Alcalá3, J. Moreno-Rubio4, S. Salinas2, F. Zambrana1, A.M. Jiménez-Gordo5, B. Sainz Jr3

Author affiliations

  • 1 Medical Oncology/precision Oncology Laboratory, Infanta Sofia University Hospital, 28702 - San Sebastián de los Reyes/ES
  • 2 Pathology, Infanta Sofia University Hospital, 28702 - San Sebastian de los Reyes/ES
  • 3 Biochemistry, Universidad Autónoma de Madrid, 28049 - Madrid/ES
  • 4 Precision Oncology Department, Infanta Sofia University Hospital, 28702 - San Sebastian De Los Reyes/ES
  • 5 Medical Oncology/precision Oncology Laboratory, Infanta Sofia University Hospital, 28702 - San Sebastián De Los Reyes/ES
More

Resources

Abstract 1359

Background

CSCs, specifically their involvement in tumor progression and chemoresistance, represents one of the cornerstones of current cancer research. CSCs autofluorescence analysis has proven to be an accurate method to detect these cells in tumor tissues, offering an ideal setting to study the prognostic and predictive implications of this marker. More importantly, it also offers a new scenario for the development of personalized screening platforms, which could be widely universalized in the hospital setting. However, a straightforward and reproducible model for the identification and isolation of autofluorescent CSCs is still lacking.

Methods

Fresh tissues from 97 resected tumors were analyzed over 24 months. The percentage of CSCs in primary tumors was analyzed using autofluorescence, the result of Riboflavin accumulation in discrete cytoplasmic vesicles over expressing the ATP-dependent transporter ABCG2. These results were correlated with the established CSCs markers CD133 and CD90. Fumitremorgine C (FTC), a specific inhibitor of ABCG2, was used to verify the specificity of the autofluorescence observed.

Results

Autofluorescent cells (AC) in the epithelial cell compartment (EpCAM+) of the tumors analyzed were identified in 60% of the samples, primarily in gastrointestinal tumors (e.g. colon, gastric, rectal). AC also co-expressed other established CSC markers, such as CD90. Autofluorescence disappeared when tumoral cells were incubated with FTC confirming that the autofluorescence observed was ABCG2-dependent.

Conclusions

CSCs can be efficiently identified and isolated from gastrointestinal tumors using autofluorescence. The simplicity of this method would allow for its applicability to the broader scientific community in order to investigate the behaviour of CSCs in tumor progression and drug resistance. Moreover, upon their isolation, AC could be used in screening platforms to assess the chemoresistance of CSCs, thus allowing for the development of new molecular targeted therapies.

Clinical trial identification

Legal entity responsible for the study

Hospital Universitario Infanta Sofía.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings